Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

Executive Summary

• Eupraxia Pharmaceuticals reported Q3 2025 results, highlighting a net loss of $6.4 M and cash of $89.0 M after completing an $80.5 M public offering.
• Phase 1b/2a RESOLVE trial 52‑week data showed two‑thirds of Cohort 5 patients (N=3) remained in clinical remission, supporting durable efficacy of EP‑104GI for eosinophilic esophagitis.
• The company projects its cash runway to fund operations and pipeline development into the first half of 2028.

Key Details

• Financing: Closed public offering on Sep 24 2025; issued 14,636,363 common shares at $5.50 per share plus an underwriter option for 1,909,090 additional shares; gross proceeds ≈ $80.5 M. Proceeds earmarked for EP‑104GI clinical development and broader pipeline.
• Clinical Update: 52‑week data (Sept 2 2025) from RESOLVE trial Cohort 5 (N=3) – 66% remained in remission; no new safety concerns. Additional 52‑week data from Cohort 6 pending later 2025. Topline Phase 2b results expected Q3 2026.
• Financials: Net loss $6.4 M for quarter ended Sep 30 2025 (vs. $6.0 M YoY). Cash balance $89.0 M (up from $33.1 M at end‑Q4 2024). Shares outstanding: 50,598,331 common; 8,905,638 preferred.
• Cash Runway: Existing cash plus anticipated in‑the‑money warrant exercises expected to fund the company into H1 2028.
• Tariff Monitoring: Management tracking potential U.S./Canada tariff impacts on clinical supply chain; maintains USD balances to mitigate FX risk.
• Share Structure: Total common shares outstanding 50,598,331; preferred shares 8,905,638.

Notable Quotes

“The compelling 52‑week data from our RESOLVE trial reported this quarter further reinforce the potential of EP‑104GI as a highly effective and durable treatment for eosinophilic esophagitis (EoE),” – Dr. James Helliwell, CEO

All forward‑looking statements are subject to risks and uncertainties detailed in the release.